Elevation Oncology Climbs 57% By Investing.com

(Updated – May 26, 2023 10:50 AM EDT)

Elevation Oncology (ELEV) Climbs 57%

• Hedge fund Point72 recently disclosed an 8.7% stake in the company
• Today’s gain appear related to early-stage data for its treatment of gastric cancer at ASCO. The abstract was for “First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors.”